BRISBANE, Calif., Jan. 12 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that it will release fourth quarter & year-end 2005 financial results on Thursday, February 2, 2006, at 4:00 p.m. ET. The Company will host a live conference call and webcast at 4:30 p.m. ET that same day.
To access the live teleconference, dial 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 4238052. To access the webcast, please log on to the Company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for ten business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international) and entering the conference ID# 4238052.
About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a broad and deep product portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes Actimmune(R) (interferon gamma-1b), pirfenidone and research programs. Actimmune(R) is being evaluated in the INSPIRE Trial, a Phase III study in patients with IPF, and pirfenidone is also being developed for the treatment of IPF in a Phase III program expected to initiate in the first half of 2006. The hepatology portfolio includes the early stage HCV protease inhibitor program and several small molecule programs in research. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.
InterMune, Inc.CONTACT: Investors: Judy Hayes of InterMune, Inc., +1-415-466-2242 orir@intermune.com; or Media: Pam Lord of Atkins + Associates,+1-858-527-3494 or plord@irpr.com, for InterMune, Inc.
Web site: http://www.intermune.com/
